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Cross-neutralization between rabies virus (RABV) and two European bat lyssaviruses (EBLV-1
and -2) was analysed using lentiviral pseudotypes as antigen vectors. Glycoprotein (G-protein)
cDNA from RABV challenge virus standard-11 (CVS-11) and EBLV-1 and -2 were cloned
and co-expressed with human immunodeficiency virus (HIV) or murine leukemia virus (MLV) gag–
pol and packageable green fluorescent protein (GFP) or luciferase reporter genes in human cells.
The harvested lentiviral (HIV) vector infected over 40% of baby hamster kidney (BHK) target cells,
providing high-titre pseudotype stocks. Tests on blinded antibody-positive (n515) and
-negative (n545) sera, predetermined by the fluorescent antibody virus neutralization (FAVN) test
approved by the World Health Organization (WHO) and Office International des Epizooties (OIE),
revealed that the CVS-11 pseudotype assay had 100% concordance with FAVN and strongly
correlated with neutralization titres (r
250.89). Cross-neutralization tests using sera from RABV-
vaccinated humans and animals on pseudotypes with CVS-11, EBLV-1 and EBLV-2 envelopes
showed that the relative neutralization titres correlated broadly with the degree of G-protein
diversity. Pseudotypes have three major advantages over live-virus neutralization tests: (i) they can
be handled in low-biohazard-level laboratories; (ii) the use of reporter genes such as GFP or
b-galactosidase will allow the assay to be undertaken at low cost in laboratories worldwide; (iii)
each assay requires ,10 ml serum. This robust microassay will improve our understanding of the
protective humoral immunity that current rabies vaccines confer against emerging lyssaviruses,
and will be applicable to surveillance studies, thus helping to control the spread of rabies.
INTRODUCTION
Rabies virus (RABV) has the highest human case fatality
rate of any viral disease, nearly 100% in individuals who
do not receive one of the available prophylaxes or post-
exposure treatment. This high mortality rate coupled with
the worldwide distribution of RABV means that approxi-
mately 55000 people are killed each year, the main burden
being borne by children in the developing world (WHO,
2006). There are effective pre- and post-exposure vaccines
that are frontline mechanisms, along with the control of
animal reservoirs, for combating the spread of the virus to
susceptible animal hosts. These vaccines stimulate the
production of virus-neutralizing antibodies (VNAs) to the
envelope glycoprotein (G-protein), similar to the immun-
ity conferred by live virus infections, where neutralizing
immune responses to RABV are directed against the viral
G-protein (Cox et al., 1977). The host immune response
also includes non-neutralizing antibodies and cell-
mediated immunity to the nucleoprotein (Dietzschold
et al., 1987). Increased monitoring of humoral responses to
RABV vaccines and studies of the prevalence of natural
RABV and lyssavirus infections in domestic and wild
species would allow for a more specific and proportionate
response in endemic countries. However, the majority of
these countries have resource-limited laboratories and the
routine method to test for RABV VNAs, in most countries,
involves high containment, biosafety level 3 facilities. Thus,
it is currently not practical to undertake thorough and
sustained surveillance as the screening cannot be under-
taken in the majority of these locations.
European bat lyssavirus type-1 (EBLV-1) and European bat
lyssavirus type-2 (EBLV-2) predominantly infect insecti-
A supplementary figure and two supplementary tables are available with
the online version of this paper.
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resulted in EBLV-1 infections of humans, sheep and a stone
marten (Fooks et al., 2003). Previous work has shown that
antibody responses in individuals vaccinated with the
RABV human diploid cell vaccine (HDCV) are able to
neutralize RABV [rabies virus (RV61) and challenge virus
standard-11 (CVS-11)], EBLV-1, EBLV-2 and Australian
bat lyssavirus (Brookes et al., 2005; Hanlon et al., 2005).
However, the same vaccine does not confer complete
protection against the emerging Eurasian lyssavirus strains
Aravan virus, Khujand virus, Irkut virus and West
Caucasian Bat virus (Hanlon et al., 2005) or against
lyssaviruses belonging to phylogroup II (Badrane et al.,
2001; Fooks, 2004; Hanlon et al., 2005).
Pseudotypes are viruses that carry the genome and core of
one virus and the envelope of another. There are many
examples of pseudotypes being used for virus receptor
identification and cell entry (Dalgleish et al., 1984; Wool-
Lewis & Bates, 1998) and for virus neutralization by
antibodies (Bartosch et al., 2003; Clapham et al., 1984;
Temperton et al., 2005). Retroviral pseudotypes [based on
the gammaretrovirus murine leukemia virus (MLV) or
lentivirus human immunodeficiency virus (HIV)] that bear
vesicular stomatitis virus (VSV) G-proteins are commonly
used as vectors for gene therapy (Naldini et al., 1996;
Takeuchi et al., 1996; Zufferey et al., 1997). In fact,
retroviral pseudotypes using RABV envelopes have pre-
viously been shown to function as neurotropic gene vectors
(Desmaris et al., 2001; Mazarakis et al., 2001; Mentis et al.,
2006). We have previously shown with SARS-coronavirus
spike S-protein and H5N1 influenza virus haemagglutinin
that retroviral pseudotypes expressing these envelope
proteins can be used in sensitive and specific assays for
the detection of VNAs to these pathogens (Temperton et al.,
2005, 2007).
Here we report the analysis of neutralizing antibodies to
CVS-11, EBLV-1 and EBLV-2 in sera from RABV-
vaccinated humans, canines and felines, using lentiviral
pseudotypes. As the only lyssavirus protein present in the
pseudotypes is the G-protein, we can accurately determine
the precise role that antibodies targeting this protein play
in cross-neutralization. Virus-neutralizing titres are corre-
lated against full-length G-protein sequences encoding the
glycoprotein. This powerful, novel assay for the detection
of RABV VNA using CVS-11 pseudotypes can be adapted
to meet the needs of many laboratories worldwide without
requiring high containment. Using pseudotypes with the
luciferase reporter, we established the assay’s sensitivity and
specificity with serum samples that were previously
characterized using the World Health Organization
(WHO) and Office International des Epizooties (OIE)
fluorescent antibody virus neutralization test (FAVN).
METHODS
Cell lines. Human embryonic kidney 293T cells (HEK-293T;
originally referred to as 293/tsAJ609neo; DuBridge et al., 1987) were
used for transfections and to determine the tropism range of the
pseudotyped virus together with the NP2 human glioma cell line
(Soda et al., 1999), baby hamster kidney 21 cells clone 13 (BHK-21;
originally obtained from the American Tissue Culture Collection as
ATCC CCL-10; Stoker & Macpherson, 1964), human rhabdomyo-
sarcoma cells (TE671; Stratton et al., 1989) and mouse neuroblastoma
cells (N2A; originally obtained from ATCC CCL-131). HEK-293T
cells were maintained in Dulbecco’s modified Eagle medium
(DMEM) supplemented with Glutamax and 15% fetal calf serum
(FCS) at 10% CO2; all other cell lines were cultured in DMEM with
10% FCS and 1% penicillin/streptomycin at 5% CO2.
Plasmids and pseudotype production. For transfection, 5610
6
HEK-293T cells were plated 24 h prior to addition of a complex
comprising plasmid DNA and Fugene 6 that facilitated DNA
transport into the cells (as described by the manufacturer; Roche).
The HIV type 1 (HIV-1) gag-pol construct pCMV-D8.91 (Zufferey
et al., 1997) and green fluorescent protein (GFP) reporter construct
pCSGW (pHR9SIN-cPPT-SGW, which incorporates the eGFP cassette
driven by the U3 part of the spleen focus forming virus long-terminal
repeat sequence; Demaison et al., 2002) or the firefly luciferase
reporter construct pCSFLW (where the luciferase gene has been
cloned into pCSGW in place of GFP; a kind gift from Dr B. Capecchi,
Novartis Vaccines and Diagnostics, Siena, Italy), were transfected
concurrently with the required envelope construct at a ratio of
1:1.5:1 mg, respectively. MLV gag-pol construct pCMVi (Towers
et al., 2000) and GFP reporter construct pCNCG [a LNCX plasmid
(CLONTECH) encoding enhanced GFP, with CMV driving expres-
sion of the RNA] or firefly luciferase reporter construct (Op De Beeck
et al., 2004) were used at the same ratio as the HIV constructs. In each
case, cells were washed 24 h post-transfection and incubated with
fresh media. Supernatants were harvested 48 and 72 h post-
transfection and titrated on HEK-293T, NP2, BHK-21, TE671 and
N2A cell lines. The remaining virus was stored at 280 uC. Fresh or
frozen pseudotype aliquots were used for virus titrations and
neutralization assays, respectively. Each round of freeze-thaw resulted
in an average loss in virus titre of 5.7% for CVS-11, 3% for EBLV-1,
5.3% for EBLV-2 and 2% for VSV pseudotype (see Supplementary
Fig. S1, available with the online version of this paper).
Viruses and envelope cloning. The RABV isolate used in this study
was CVS-11 (ATCC VR-959). Its G-gene sequence was amplified
using the RT-PCR Titan kit as described by the manufacturer
(Roche), with primers that were designed based on the published
sequence (GenBank accession number EU352767). EBLV-1 (isolate
RV 9) and EBLV-2 (isolate RV 1787) G-gene sequences (GenBank
accession numbers EU352768 and EU352769, respectively) were
subcloned from existing transfer plasmids using specific PCR primer
sets. Primers are listed in Supplementary Table S1. The PCRs
introduced unique KpnI and XhoI restriction sites at the 59 and 39
ends of the genes. Once amplified, they were ligated into pI.18, a
pUC-based plasmid incorporating the human cytomegalovirus
immediate early promoter (Cox et al., 2002), and sequenced to
ensure correct alignment.
The VSV G-protein (Indiana serotype) expression vector pMD.G has
been described previously (Naldini et al., 1996) and was used to create
a control pseudotype virus.
Western blot. CVS-11, DEnv (where only the plasmids containing
gag-pol and reporter gene were transfected into cells), HIV and VSV
pseudotyped viral particles were purified on a 25/40% sucrose
cushion to remove any G-protein not incorporated into the viral
envelope before being separated by SDS-PAGE. Cell extracts for
Western blots were prepared by resuspending 1610
6 HEK-293T cells
(72 h post-transfection) in SDS-PAGE loading buffer (100 mM Tris/
HCl, pH 6.8; 20%, v/v, glycerol; 143 mM 2-mercaptoethanol; 10%,
Cross-neutralization of lyssaviruses
http://vir.sgmjournals.org 2205v/v, SDS; and 0.025%, w/v, bromophenol blue). Proteins were
transferred, using semi-dry equipment, to a PVDF transfer membrane
(Hybond-P; Amersham Biosciences) and blotted with SNB1, a
primary mouse anti-RABV G-protein monoclonal antibody (1:500;
a kind gift from Merial). Immunoblots for VSV G-protein were
performed using an anti-VSV G-protein monoclonal antibody (clone
P5D4; 1:10000; Sigma). To determine protein loading/transfer, an
identically loaded gel was stained with Coomassie blue and the
nitrocellulose membrane was blotted with two anti-HIV-1 Gag p53/
p24 antibodies (EVA365 and EVA366 diluted 1:100; AIDS Reagents,
NIBSC) or an anti-actin antibody able to detect all isoforms (diluted
1:750; Sigma). For all blots, an anti-mouse horseradish peroxidase-
conjugated IgG secondary antibody (diluted 1:5000; Amersham
Biosciences) was then used prior to antibody binding detection by
enhanced chemiluminescence (Amersham Biosciences).
Serum samples. Varied samples comprising sera from RABV-
vaccinated humans, dogs and cats and the OIE standard reference
dog serum diluted to 0.5 IU ml
21 with Stabilzyme (Surmodics Inc.)
were tested. Detailed descriptions of each serum are given in
Supplementary Table S2. To determine the stringency of the assay,
a total of 60 serum samples were used; these were 48 dog (40/8,
negative/positive; as initially determined by FAVN), nine cat (5/4)
and three human (0/3) sera. An additional rabbit serum, raised
against EBLV-2, was used for the cross-neutralization experiments.
Sera were titrated using twofold serial dilutions to obtain the IC100.
All experiments were undertaken at least in duplicate; if the titre
varied by more than one doubling dilution it was repeated a third
time and the geometric mean was recorded, in keeping with standard
serological practice (Bresson et al., 2006).
Neutralization assays. Live virus experiments were undertaken
using the FAVN as described previously using CVS-11 (Brookes et al.,
2005; Cliquet et al., 1998). Pseudotype TCID50 values were calculated
using the end point method (Condit, 2001); the CVS-11 pseudotype
was serially diluted in multiple replicates which resulted in infection
of all replicates at low dilutions, no infection at high dilutions and
infection in some but not all inoculations at intermediate dilutions.
The dilution of virus that resulted in infection of 50% of replicates
could then be calculated.
In a 96-well plate, 906TCID50 CVS-11 pseudotyped virus that
resulted in an output of 8610
5 relative light units (RLU) was
incubated with doubling dilutions of sera for 1 h at 37% (5% CO2)
before the addition of 1610
4 BHK-21 cells. These were incubated for
a further 48 h, after which 125 ml medium was removed and 75 ml
Bright-Glo reagent (Promega) was added. Luciferase activity was
detected 2.5 min later by reading the plates on a Glomax 96
microplate luminometer (Promega). End-point titres (which are
equivalent to IC100 values) were chosen, as used in FAVN tests. Our
initial experiments using GFP reporter proteins were analysed by
fluorescence microscopy and by flow cytometry (FACScan; BD). For
all results, background RLU (virus alone or DEnv) or GFP (cells
alone) was deducted before analysis.
Cross-neutralization experiments were performed as above with the
following mean pseudotype input (RLU): CVS-11, 5.4610
5; EBLV-1,
4.5610
5; EBLV-2, 4.2610
5.
RESULTS
Expression of RABV G-protein and production of
pseudotype particles
To determine whether the viral G-proteins were being
expressed on the envelope of the pseudotype virus, we
performed a Western blot using supernatant from
transfected cells and a RABV monoclonal antibody
(SNB1). The viral particles were purified from cell
supernatant using a sucrose cushion to ensure that no
secreted envelope was present in the samples. We were able
to detect RABV envelope protein in the CVS-11 sample
only (lane 1; Fig. 1a). No RABV G-protein was detected in
the three negative control lanes (2–4) representing DEnv,
HIV and VSV. To compare the level of CVS-11 G-protein
expression on pseudotype particles with that of other viral
envelopes, we blotted for VSV G-protein associated with a
VSV pseudotype particle and observed similar levels of
expression to CVS-11 (Fig. 1b). Subsequent blotting of the
membrane with anti-HIV-1 Gag p53/p24 antibodies
confirmed the presence of lentiviral particles (Fig. 1c).
Protein loading was established by running an identical
SDS gel and staining it with Coomassie blue (Fig. 1d). We
observed high, and comparable, expression of CVS-11
(Fig. 1e), VSV G-protein (Fig. 1f) and HIV-1 p53 (Fig. 1g)
when extracts from cells used to produce CVS-11 or VSV
pseudotypes were analysed. An actin control was used to
ensure equal protein loading (Fig. 1h).
CVS-11 pseudotype virus preparations were made by
packaging either GFP or firefly luciferase as a reporter
gene and marker of infection. These were titrated on cell
lines known to be permissive for infection with wild-type
RABV, i.e. BHK and N2A cells, and others that had
previously not been tested: 293T, TE671 and NP2.
Luciferase-pseudotyped virus with an HIV (lentiviral) core
produced up to 2.5 log10 higher viral titres (Fig. 2a) than an
MLV (gammaretroviral) core (Fig. 2b). Conversely, GFP-
MLV virus (Fig. 2b) was more potent than GFP-HIV
(Fig. 2a), except on BHK cells. The 293T and TE671 cell
lines were highly permissive for both the GFP and
luciferase CVS-11 pseudotypes, but BHKs gave the
strongest results for HIV-based pseudotypes, and the
highest luciferase titre overall. NP2 cells appeared to be
almost entirely refractory to infection, while N2As were
only permissive for MLV-based pseudotypes. All the results
for luciferase and GFP virus across the different cell lines
correlated, with the exception of the MLV virus stocks on
BHK cells. These results indicate that the HIV vector
titrated on BHK cells yielded the most sensitive system for
CVS-11 pseudotypes. We recorded an approximate GFP
pseudotype titre of 1.3610
5 IU ml
21 for CVS-11
pseudotypes and 6.5610
6 IU ml
21 for pseudotype virus
with the VSV G-protein. Since BHK cells are also used for
FAVN assays, it allowed a direct comparison of neutral-
ization as described below.
Sensitivity of the neutralization assay using a
CVS-11 pseudotype
In order to determine whether incubating varying amounts
of pseudotype with antibody affected IC100 titres, increas-
ing logs of pseudotypes were used in neutralization
assays with the OIE reference standard, plus medium-titre
E. Wright and others
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tion was determined by TCID50 and by luciferase RLU.
Using an input of 10006TCID50 (1610
7 RLU), the OIE
standard positive control (0.5 IU ml
21) could not achieve
complete neutralization (Table 1). However, when the
input was decreased to 1006TCID50 (1610
6 RLU) and
then 106TCID50 (1610
5 RLU), the OIE standard was able
to neutralize 100% at greater dilutions. The same effect
was observed using sera from a feline (RC-195) and
another canine (RC-199) sample. Thus, as the level of
virus/antigen input increased, there was a concomitant
decrease in the VNA titre (Table 1).
Having established the working concentration of the
luciferase pseudotype virus, we tested 50 blinded sera from
RABV vaccine recipients to an end point of four doubling
dilutions initially, to determine which samples were the
negatives or failures (,0.5 IU ml
21; Fig. 3a). There were 44
of these, with poor or no response that gave insufficient
protection according to OIE/WHO criteria, and six clearly
positive sera with differing titres. The six positive sera were
tested at a higher serum dilution in tandem with a further
nine positive samples, blinded with respect to their FAVN
neutralization titres (Fig. 3b). When unblinded, these
results mirrored those obtained using the FAVN test. A
panel of low-, medium- and high-titre RABV-specific sera
failed to neutralize pseudotypes bearing the VSV G-protein
(data not shown).
To determine how sensitive the pseudotype assay was at
differentiating between serum samples with different
neutralizing titres, we compared the titres obtained using
the pseudotype assay with FAVN titres. The two sets of
titres correlated strongly, with those sera that had a high IU
ml
21 reading also scoring a higher dilution result (Table 2).
These data also showed that different animal species (feline,
canine, human) elicited a range of strong and weak VNA
responses to RABV. Taken together and presented as a
scatter plot, the results obtained revealed a high correlation
coefficient (r
250.89) between pseudotype and FAVN titres
(Fig. 3c).
Cross-neutralization of CVS-11 and European bat
lyssaviruses
Having established a working protocol for the accurate
determination of CVS-11 virus-neutralizing antibodies, we
adapted the assay to detect humoral responses to
pseudotypes bearing G-proteins from representative iso-
lates of EBLV-1 and EBLV-2. We could then study what
effect antibodies that specifically target the G-protein alone
have on cross-neutralization, and whether any animal
species elicit a more potent response than others.
The titre of pseudotype virus obtained with EBLV-1 and
EBLV-2 G-protein pseudotypes was comparable to that for
CVS-11 and within a log10 of the titre achieved with VSV
G-protein (Fig. 4a).
We therefore compared the patterns observed for VNA
responses of RABV antisera from different animals with
different lyssaviruses (Fig. 4b). Human serum samples
neutralized CVS-11 to the greatest degree, followed by
Fig. 1. Expression of RABV-G, VSV-G and HIV-1 capsid proteins
in pseudotypes and producer 293T cells. (a) An anti-RABV G-
protein antibody was used in a Western blot of purified
pseudotype samples with envelope glycolproteins of CVS-11
(lane 1), DEnv (lane 2), HIV (lane 3) and VSV (lane 4). (b) A
comparative immunoblot for VSV was undertaken using an anti-
VSV G-protein antibody. (c) Protein transfer was measured by
blotting the membrane with antibodies to p53 and p24 of HIV-1.
(d) An identical SDS gel was stained with Coomassie blue to
determine total protein loading. Cells used to produce CVS-11
(lane 5) and VSV (lane 6) pseudotypes were harvested 72 h post-
transfection and lysed in SDS-PAGE loading buffer. Extract
equating to 410
4 cells was separated by SDS-PAGE and the
levels of CVS-11 G-protein (e), VSV G-protein (f), HIV-1 p53/24
(g) and actin (h) were determined using monoclonal antibodies. *,
p53 and p24 staining.
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was observed in cats. The sera from dogs neutralized all
three genotypes, but no obvious pattern was common to
these samples. Antibodies in the rabbit serum also
neutralized all three pseudotypes, with the greatest
neutralization observed with EBLV-2. When all nine
neutralizing responses against CVS-11 and EBLV-1 were
compared (Fig. 4c), there was a correlation coefficient of
0.79, while that between CVS-11 and EBLV-2 was 0.90
(Fig. 4d) and between EBLV-1 and EBLV-2 was 0.68
(Fig. 4e). Analysis of the full-length G-protein amino acid
sequences used here revealed that they have a similar
degree of divergence from each other, with EBLV-1 and
EBLV-2 (80%) being marginally more closely related to
each other than to CVS-11 (70.1 and 73.7% respectively;
Table 3). The r
2 values for CVS-11 versus EBLV-1 and
CVS-11 versus EBLV-2 rank in inverse order to the degree
of amino acid diversity of their respective G-proteins.
DISCUSSION
Our pseudotype particles that express RABV envelope/G-
proteins are antigenically similar to those native proteins
on wild-type, live RABV virus particles, which function to
allow particle entry and are neutralized by anti-RABV sera.
Using an antibody shown previously to detect RABV G-
protein, we were able to detect these proteins in
immunoblots conducted with our CVS-11 pseudotype
virus. This antibody does not detect G-protein in DEnv
virus (lacking a RABV envelope glycoprotein) or on
pseudotypes bearing either the HIV envelope or VSV G-
protein, although VSV and RABV are members of the same
virus family, Rhabdoviridae. However, using a VSV-G
monoclonal antibody, we observed the same, if not
marginally less, incorporation of the envelope protein into
the pseudotype. The levels of CVS-11 and VSV G-protein
expression are also comparable in the transfected 293T
producer cells, suggesting that the G-proteins incorporate
with equal efficiency into the pseudotypes. As expected, the
cleaved Gag p24 protein predominates in the mature
pseudotype particle and the unspliced Gag p53 predomi-
nates in the 293T cells.
The use of replication-competent isolates of highly
pathogenic viruses is strictly regulated and, in the majority
of countries, requires the use of category 3 or 4
Fig. 2. Cells permissive for the CVS-11 pseudotype virus. Aliquots of virus (50 ml) with a lentiviral (HIV; a) or a retroviral (MLV;
b) core were incubated with different cell lines to determine the most appropriate cell type to use in further assays. GFP results
are shown as fluorescence micrographs and mean proportions of infected cells (determined by flow cytometry). Viral titres for
luciferase pseudotypes are given in RLU (mean±SD) and titres reported are after deduction of the background luciferase activity
of DEnv pseudotypes observed on each cell line.
Table 1. Effect of varying levels of pseudotype input on
neutralization titres
Sera were classified as low, medium or high by their FAVN titre
Sera Pseudotype virus input
(RLU/TCID50)
110
5/10 110
6/100 110
7/1000
Low (0.5 IU ml
21;
OIE standard)
40 20 ,20
Medium (23.4 IU ml
21;
RC-199)
2560 1280 320
High (364.5 IU ml
21;
RC-195)
20480 10240 320
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we have constructed modified lentiviral vectors and
established an assay that utilizes these replication-incom-
petent particles to measure RABV VNA titres accurately.
This method has the benefit of allowing experiments to be
undertaken in category 2 biosafety laboratories, since the
pseudotype is unable to replicate and cause a productive
infection. The assay also benefits from detecting VNA
alone, in contrast to ELISA, but similar to FAVN, gives a
more accurate picture of the protective antibodies present
in the sample. Over 60 sera from various host species were
evaluated for neutralizing antibodies against the CVS-11 G-
protein. The results show that the pseudotype assay is
100% specific and equally sensitive compared with the
WHO/OIE-approved FAVN assay, as shown by effective
differentiation between positive and negative sera and by
accurately reflecting VNA titres for the positive sera.
It has been reported that human sera from recipients of the
RABV HDCV can cross-neutralize EBLV-1 and EBLV-2
(Brookes et al., 2005; Hanlon et al., 2005). Confirmation of
these observations using pseudotypes is consistent with the
notion that G-protein is the target for neutralizing
antibody because it is the only lyssavirus protein present
in the pseudotype particle. Furthermore, our results show
that antibodies in serum from vaccinated animals,
specifically targeting the G-protein, cross-neutralize dis-
tinct lyssavirus genotypes to varying titres depending on
viral genotype and the animal that the serum was obtained
from. G-protein antibody responses in humans and cats
were higher against CVS-11 infections, followed by EBLV-2
and finally EBLV-1, but additional samples need testing to
confirm this observation. This result is to be expected to
some extent, given that the samples were from RABV-
vaccinated individuals. As expected, the rabbit serum,
which was raised against EBLV-2, neutralized this genotype
at higher dilutions than CVS-11 and EBLV-1.
Fig. 3. Comparison of neutralizing titres using FAVN and RABV
lentiviral pseudotype reveals high specificity and sensitivity. (a) To
determine the specificity of the assay, 50 blinded serum samples
were tested. All 44 negative and six positive samples (by FAVN)
were identified correctly. (b) Fifteen positive samples were
subsequently tested to determine the sensitivity of the neutraliza-
tion assay using lentiviral pseudotypes. (c) The results obtained for
each sample tested were plotted on a scatter plot showing the
correlation between FAVN and pseudotype results given in IU ml
”1
and dilution respectively. The position of negative sera is shown in
light print; two positive samples have the same IU and dilution
values, so appear as one point.
Table 2. FAVN and pseudotype neutralizing titres for all serum
samples
Serum ID Species FAVN
(IU ml
”1)
Pseudotype
(dilution)
OIE standard Canine 0.5 20–40
PET-5825 Canine 0.9 40–80
PET-1333 Canine 1.5 40–80
PET-1326 Canine 4.5 160
PET-1329 Canine 10.3 320–640
RC-175 Human 23.4 640–1280
RC-199 Canine 23.4 1280
PET-1335 Feline 23.4 1280
RC-248 Feline 30.8 2032
RC-200 Canine 30.8 2560
2857 Human 53.0 1280–2560
RS-174 Human 121.5 10 240
RC-215 Canine 210.4 1280–2560
RC-195 Feline 364.5 10240
PET-1310 Feline 631.3 20480
Negative samples
(n545)
Canine (n540)
Feline (n55)
,0.5 ,20
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or EBLV-2 support the hypothesis that the higher the
degree of similarity between G-protein sequences the more
comparable the neutralization titres (Brookes et al., 2005;
Hanlon et al., 2005). The lower r
2 value for EBLV-1 versus
EBLV-2 does not support this hypothesis, however, as the
EBLVs have a higher sequence identity to each other than
to CVS-11. It is likely that this is due to all but one of the
sera used in these experiments being raised only against
RABV-based vaccines. In addition, the small sample size
and individual variation may influence the results. This
illustrates the difficulties in interpretation of antigenic
differences using cross-neutralization data. A wider study
using multiple representatives from each genotype, with
sera raised against multiple genotypes, may assist in further
quantifying antigenic differences between lyssaviruses.
The cross-neutralization of lentiviral pseudotypes bearing
lyssavirus envelopes will provide the opportunity to analyse
neutralizing epitopes in G-proteins quantitatively and
qualitatively. The method described here can be extended
to other lyssaviruses in phylogroups 1 and 2. Because
cDNA cloned into plasmids is used to generate the
pseudotype, site-specific mutagenesis can be exploited to
elucidate which domains are crucial for G-protein function
Fig. 4. Cross-neutralization of RABV and bat lyssaviruses by rabbit, human, canine and feline sera. (a) EBLV-1 and EBLV-2
pseudotypes with GFP and luciferase reporters (50 ml) were tested on BHK cells alongside CVS-11, DEnv and VSV controls.
(b) IC100 VNA titres for rabbit, human, canine and feline sera are reported for CVS-11, EBLV-1 and EBLV-2 luciferase
pseudotypes and scatter plots with correlation co-efficients comparing CVS-11 and EBLV-1 (c), CVS-11 and EBLV-2 (d) and
EBLV-1 and EBLV-2 (e) are given. The position of negative sera is shown in light print (c, e); two positive samples in (c) and (d)
had the same serum dilution value for both viruses, so they appear as one point. For (c), (d) and (e), n59.
Table 3. G-protein nucleotide and amino acid sequence
identities for CVS-11, EBLV-1 and EBLV-2
Values above the diagonal refer to nucleotide identities; values below
the diagonal refer to amino acid identities
Virus CVS-11 EBLV-1 EBLV-2
CVS-11 66.3 69.8
EBLV-1 70.1 73.2
EBLV-2 73.7 80.0
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neutralizing epitopes determine strain-specific and group-
specific responses to sera and to monoclonal antibodies.
For the adoption of neutralization assays, using either
replication-competent or pseudotypeviruses, there aresome
issues that need to be addressed before the assay can be
employed for routine serological surveillance. In both
systems, there will be free or secreted envelope protein in
the virus preparations that can adsorb antibody from the
supernatantandthusskewneutralization tests.Itistherefore
important to standardize virus input in order to obtain the
most sensitive and reliable results. This can be achieved by
determining the concentration of virus at which a known
negative serum becomes positive, and by using a concen-
tration of virus slightly greater than that routinely used by
rabies reference laboratories as part of their assay validation
process. Alternatively, where a baseline positive control is
available, for example the OIE reference standard for RABV
neutralization assays, the smallest amount of virus that is
needed to achieve an IC100 at the lowest serum dilution
could be determined. This will allow for the greatest range of
serum dilutions to be tested, while all negative samples will
provide a ‘failed’ result. For our assay, this result was
achieved using a virus input between 106TCID50 (1610
5
RLU) and 1006TCID50 (1610
6 RLU). Therefore, we
would recommend 10–1006TCID50 or 1610
5–1610
6
RLU virus input for neutralization assays using the CVS-
11 pseudotype. While background readings for cells alone or
virus alone were 50–200 RLU, luciferase carry-over for DEnv
samples and those pseudotypes that produced a negative
GFP result was up to 1610
4 RLU, depending on the cell line
used (with 50 ml pseudotype input). Therefore, the DEnv
value should be considered the cut-off for a positive viral
titre when using large volumes of pseudotype. However, as
only 0.1–0.5 ml of pseudotype virus is normally used, the
‘virus alone’ luciferase reading is generally larger than that
which would be observed with DEnv and is therefore used as
the background value.
It was encouraging to observe that BHK cells, which are
routinely used in live virus CVS-11 FAVN tests, were highly
permissive for our CVS-11 pseudotype. Conversely, N2A
cells that were readily infected by live lyssaviruses were not
permissive for the CVS-11 pseudotype with HIV core. In
contrast, MLV-based pseudotypes, made using different
reporter constructs, were able to infect N2A cells,
suggesting a post-entry restriction imposed selectively on
the lentiviral reporter gene in the vector. This could be due
to a specific restriction of the pCSGW and pCSFLW
promoter in this cell line, because N2A cells were also
almost completely refractory to infection by VSV, EBLV-1
and EBLV-2 pseudotypes produced with the same HIV
reporter plasmids (data not shown). Alternatively, the
lentiviral core may be subject to a post-penetration
restriction in N2A cells, such as TRIM5a (Towers, 2007).
The fatality rate of RABV infections in humans who have
not received either pre- or post-exposure prophylaxis is
very high, nearing 100%. Compared with the diseases
caused by other highly pathogenic viruses, such as Ebola
virus haemorrhagic fever (80% fatality) and H5N1
influenza (61%), the ongoing research and surveillance
for RABV is limited, supporting the suggestion that rabies
is a ‘neglected disease’, especially in rabies-endemic
countries in Africa and Asia (WHO, 2006; Fooks, 2005).
There is, therefore, a need to readdress this balance by
increasing the current level of surveillance for RABV in
countries where the infection causes high levels of
mortality. This would also help to limit misdiagnosis and
consequent underreporting of RABV infection (Mallewa
et al., 2007). The main assay currently being used (FAVN)
provides good sensitivity and specificity, but requires
handling of live RABV. Alternative assays for the detection
of RABV antibodies, such as ELISA (Cliquet et al., 2004)
and rapid fluorescent focus inhibition test-GFP (Khawplod
et al., 2005), have been designed; however, the former does
not differentiate between neutralizing and non-neutralizing
antibodies and the latter still requires high containment-
level facilities.
The use of pseudotypes for the detection of VNAs removes
the need to use live viruses and provides both high
sensitivity and high specificity for the detection of
neutralizing antibodies. Incorporation of GFP or luciferase
as a reporter gene makes this assay applicable to many
laboratories involved in RABV surveillance, and a good
candidate for high throughput screening. For laboratories
lacking fluorescence or luciferase detection, a b-galactosi-
dase reporter could be used. It is also amenable to testing
for the presence of antibodies in small volumes of sera
(microassay) such as may be obtained from bats. In
conclusion, this report shows that it is possible to analyse
cross-neutralizing antibody responses against different
lyssavirus genotypes using lentiviral pseudotypes. This
approach could greatly improve the surveillance of new
and emerging lyssaviruses and evaluation of the protection
that current vaccines offer against these pathogens.
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